NCT06533267 Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma.
| NCT ID | NCT06533267 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sun Yat-sen University |
| Condition | Nasopharyngeal Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 442 participants |
| Start Date | 2024-03-25 |
| Primary Completion | 2034-03-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 442 participants in total. It began in 2024-03-25 with a primary completion date of 2034-03-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to compare the survival and adverse reactions differences between endoscopic surgery and intensity modulated radiotherapy for patients with newly diagnosed stage Ⅰ nasopharyngeal carcinoma, aiming to verifying the efficacy and safety of endoscopic surgery for stage Ⅰ nasopharyngeal carcinoma.
Eligibility Criteria
Inclusion Criteria: * Karnofsky score \>70. * Non-keratinized carcinoma of the nasopharynx (differentiated or undifferentiated, i.e., WHO type II or III) or carcinoma in situ confirmed histologically and/or cytologically. * According to the eighth edition of UICC/AJCC staging, the patient was defined as T1N0M0 stage I. * The maximum short diameters of retropharyngeal lymph nodes and cervical lymph nodes were not more than 0.4cm and 0.6cm respectively, or retropharyngeal lymph nodes and cervical lymph nodes were 0.4-0.5cm and 0.6-1.0cm respectively but PET/CT showed negative. * Informed Concent signed with willingness to obey the follow-up, treatment, examination and any other programs according to the research protocol. Exclusion Criteria: * MRI showed that the primary tumor diameter \>1.5cm, or internal carotid artery vascular malformation which would seriously affect the operation. * Diagnosed as recurrent or distant metastatic nasopharyngeal carcinoma or together with any other malignancy. * Suffering severe organ dysfunction or physical disorder which could not tolerate operation or radiotherapy. * Unable to cooperate with regular follow-up due to psychological, social, domestic or geological reasons.
Contact & Investigator
Ming-Yuan Chen, MD,PhD
PRINCIPAL INVESTIGATOR
Sun Yat-sen University
Frequently Asked Questions
Who can join the NCT06533267 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Nasopharyngeal Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06533267 currently recruiting?
Yes, NCT06533267 is actively recruiting participants. Contact the research team at chmingy@email.sysu.edu.cn for enrollment information.
Where is the NCT06533267 trial being conducted?
This trial is being conducted at Zhuhai, China.
Who is sponsoring the NCT06533267 clinical trial?
NCT06533267 is sponsored by Sun Yat-sen University. The principal investigator is Ming-Yuan Chen, MD,PhD at Sun Yat-sen University. The trial plans to enroll 442 participants.